Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-06 Drugs used in neutropenia
| Filgrastim |
|
Formulary
|
Injection 12 million units in 0.2mL prefilled syringe, 30 million units & 48 million units in 0.5mL prefilled syringe Specialist initiation only. |
 MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome |
|
| Pegfilgrastim |
|
Formulary
|
Injection 6mg in 0.6mL prefilled syringe Specialist initiation only. |
|
MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome |
|
|
Links
LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- MHRA Drug Safety Update Sept 2013: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA Drug Safety Update September 2013: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- MHRA: Filgrastim and pegfilgrastim: risk of capillary leak syndrome
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease